All the studies mentioned the efficacy of KD in CDKL5-related epilepsy, and four of them [22, 24, 25, 27] clearly defined the efficacy, with an overall responder rate of 11.8% (4/34). The gene discussed is CDKL5; the disease is epilepsy.